Home › Gastrointestinal Stromal Tumors › Texas
Gastrointestinal Stromal Tumors clinical trials in Texas
7 studies for Gastrointestinal Stromal Tumors are looking for participants at sites in Texas.
Cities in Texas
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- The University of Texas MD Anderson Cancer Center - Texas Medical Center, Houston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06760819DESTINY-PANTUMOUR04
- Research Site, Dallas
RecruitingObservational study
Ages 18 to 130 · All sexes · Updated Sep 25, 2026 · NCT07124000A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
- GSK Investigational Site, Dallas
- GSK Investigational Site, Houston
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07218926KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting (SynerGIST-1st Line)
- UT MD Anderson Cancer Center, Houston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 10, 2026 · NCT07406633A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- Baylor Scott & White Research Institute, Dallas
- University of Texas MD Anderson Cancer Center, Houston
- Baylor Scott & White Medical Center, Temple
RecruitingPhase 2
Ages 8 and older · All sexes · Updated Jul 27, 2026 · NCT05503797A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
- Sarah Cannon Research Institute, Dallas
- University of Texas, Houston
- University of Texas Health Science Center, San Antonio
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Feb 5, 2026 · NCT06655246A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
- The University of Texas MD Anderson Cancer Center, Houston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 23, 2025 · NCT06805825From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.